Imetelstat inhibits growth of megakaryocyte colony-forming units from patients with essential thrombocythemia

Blood Adv. 2019 Nov 26;3(22):3724-3728. doi: 10.1182/bloodadvances.2019000167.

Abstract

  1. Clinically relevant imetelstat concentrations significantly inhibit CFU-MEG formation from MNCs of ET patients and reduce hTERT expression.

  2. However, similar concentrations of imetelstat do not inhibit cytokine-induced CFU-MEG from MNCs of healthy donors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alleles
  • Amino Acid Substitution
  • Biomarkers
  • Cell Differentiation / drug effects*
  • Enzyme Inhibitors / pharmacology*
  • Female
  • Humans
  • Janus Kinase 2 / genetics
  • Male
  • Megakaryocyte Progenitor Cells / cytology
  • Megakaryocyte Progenitor Cells / drug effects*
  • Megakaryocyte Progenitor Cells / metabolism*
  • Megakaryocytes / cytology
  • Megakaryocytes / drug effects
  • Megakaryocytes / metabolism
  • Middle Aged
  • Mutation
  • Oligonucleotides / pharmacology*
  • Thrombocythemia, Essential / drug therapy
  • Thrombocythemia, Essential / etiology
  • Thrombocythemia, Essential / metabolism*

Substances

  • Biomarkers
  • Enzyme Inhibitors
  • Oligonucleotides
  • JAK2 protein, human
  • Janus Kinase 2
  • imetelstat